How did you evaluate these telehealth providers?

We applied five criteria: 503A regulatory transparency (does the provider name its pharmacy partner and operate under a clinically significant difference framework?), pricing transparency with full dose-tier disclosure, provider evaluation rigor (real clinical intake versus rubber-stamp), cancellation and refund clarity in plain English, and state availability. Affiliate status is disclosed per provider in the TL;DR table. Non-affiliate competitors are named in honorable mentions to demonstrate editorial independence.

Is compounded GLP-1 through these telehealth providers legal in 2026?

Yes, when prepared by a licensed 503A pharmacy under a valid patient-specific prescription with a documented clinically significant difference, or by an FDA-registered 503B outsourcing facility under its framework. Compounded products are never FDA-approved as finished products, but compounding itself is explicitly permitted under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Can I switch telehealth providers without losing my dose progress?

Generally yes, with caveats. A new provider's prescriber will typically restart at a lower dose to verify tolerability, regardless of where the previous provider had you. Bring documentation of your dose history, any adverse events, and your reason for switching. Refund and cancellation timing varies — read the specific provider's terms before signing up at the new place. Continuity of GLP-1 therapy without long gaps is preferable to interrupted cycles.

How fast can I get started with a telehealth GLP-1 prescription?

Most reputable telehealth GLP-1 providers complete the intake, prescriber review, and prescription within 24-72 hours, with shipping in an additional 2-7 days depending on the pharmacy partner and location. Some providers expedite for an additional fee. Skipping the clinical intake is a red flag, not a feature.

What is the cheapest way to access FDA-approved branded Wegovy or Zepbound?

For commercially insured patients, the manufacturer savings cards from Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) can bring monthly cost as low as $0-$25, with eligibility restrictions. Without insurance, telehealth cash-pay programs through providers like Ro, Hims and Hers, and Sesame Care typically run $299-$499/mo for the branded products. Retail without any program runs $1,000-$1,350/mo. Verify eligibility and current pricing directly.

Best Telehealth for Weight Loss in 2026: Honest Rankings (8 Providers Compared)

Q: What is the best telehealth provider for weight loss in 2026?

There is no single best for everyone. Among the providers we evaluated, SkinnyRx leads on 503A compounded value pricing, SHED leads on dose-tier price transparency, GobyMeds leads on starter-bundle structure, Peter MD leads for men 35-55 wanting GLP-1 plus TRT/NAD+/Sermorelin in one place, and Embody GLP1 leads on the lowest documented entry tier. For users prioritizing branded FDA-approved Wegovy or Zepbound at cash pay, Ro, Hims and Hers, and Sesame Care are honorable mentions. The right pick depends on whether price, transparency, formulation options, or branded access is the top priority. (Eden Health affiliate program paused 2026-05-21.)

Q: Which telehealth provider has the lowest monthly price for compounded semaglutide?

As of May 2026, SkinnyRx starts at approximately $129/mo at the entry tier, with prices scaling with dose. SHED starts at $199/mo. GobyMeds runs $169/mo standard with a 12-week starter at $299. Embody GLP1 has the lowest documented entry tier when active. Verify current pricing directly with each provider; pricing changes frequently in this category.

Q: Are these providers safer than buying research peptides online?

Categorically yes, in regulatory terms. Telehealth providers operating through licensed 503A pharmacies or registered 503B facilities are inside the regulated compounding framework: prescriber involvement, patient-specific prescriptions, USP testing standards, and Certificates of Analysis on request. Research peptide sellers labeled 'not for human consumption' are explicitly outside that framework. Whether 'safer' is the right word depends on the individual product and prescriber relationship, but the regulatory gap is real and meaningful.

Q: What are the red flags for an untrustworthy telehealth GLP-1 provider?

Refusing to name the pharmacy partner; pricing below roughly $100/mo for compounded semaglutide; no real clinical intake (rubber-stamp prescribing); marketing claims that compounded products are FDA-approved; offering retatrutide as if it were available (it is investigational and NOT FDA-approved); no Certificate of Analysis available on request; crypto-only or gift-card payment; or social-media-only ordering channels. Each red flag independently is concerning; multiple together is a reason to walk away.

How we evaluated (methodology)

The 2026 telehealth GLP-1 market includes dozens of operators with widely varying regulatory standing, pricing transparency, and editorial conduct. We evaluated providers on five criteria that we believe matter most to a consumer making a real decision, weighted equally:

1. 503A regulatory transparency

Does the provider name its pharmacy partner publicly or on request? Does the compounded product operate under a documented clinically significant difference framework (combination products, intermediate doses, formulation changes for tolerability) — not under the now-expired shortage exception? A provider that will not name its pharmacy partner or that markets compounded products as "FDA-approved" is automatically excluded from our rankings, regardless of commission rate. For context on the regulatory framework see our explainer on whether compounded semaglutide is legal in 2026.

2. Pricing transparency with dose-tier disclosure

Compounded GLP-1 pricing scales with dose. A provider that advertises only the entry-tier price without disclosing what the price becomes at higher maintenance doses is hiding ball. We rewarded providers that publish the full dose-tier table, and downgraded those that buried the higher-tier pricing in fine print or behind sign-up walls.

3. Provider evaluation rigor

Does the platform run a real clinical intake — medical history, current medications, contraindication screening — with a licensed prescriber reviewing the case? Rubber-stamp prescribing where the questionnaire takes 90 seconds and approval is automatic is a regulatory and clinical liability. The reputable operators take 24-72 hours for prescriber review and reject ineligible candidates.

4. Cancellation and refund clarity

Plain-English cancellation terms accessible before sign-up are a signal of operator confidence. Buried cancellation flows, auto-renewals without notice, or restocking fees on unopened vials are a signal of revenue-engineering ahead of customer trust.

5. State availability and shipping

Some providers do not operate in every state due to telehealth licensure variation. Real coverage maps published openly, plus realistic shipping timelines, beat vague "available in most states" copy.

Affiliate status does not factor into the ranking criteria themselves. Affiliate status is disclosed transparently in the TL;DR table column so readers can apply their own discount to our verdict if they wish. Non-affiliate competitors are included in honorable mentions specifically to demonstrate editorial independence — if our rankings were simply commission-optimized, we would not name Hims and Hers, Ro, Sesame Care, Henry Meds, or Mochi Health at all.

The rankings — affiliate providers

#1 — SkinnyRx (Affiliate partner)

Best for: Lowest sustainable 503A compounded entry pricing with named pharmacy partner.

Entry price: ~$129/mo at the starter dose, scaling with tier (as of May 2026; verify with provider).

What we like: Pricing transparency is above category average. The 503A pharmacy partner is named on request and operates under a documented clinical-difference framework. Cancellation terms are stated in plain English on the platform.

Trade-offs to know: Higher dose tiers reach the $200-$249 range — not unusual for the category, but verify the maintenance tier price before committing. State availability is broad but not universal.

Who should pick this: Users prioritizing the lowest entry-tier price among 503A compounded providers, willing to verify dose-tier pricing themselves.

Read the SkinnyRx vs Hims head-to-head for the compounded-versus-branded comparison. (Affiliate link — see disclosure.)

#2 — SHED (ShedRx) (Affiliate partner)

Best for: Dose-tier pricing transparency and patient education.

Entry price: ~$199/mo starting tier, with full dose-tier table published (as of May 2026; verify with provider).

What we like: SHED publishes the full price ladder up front, including what the maintenance dose costs. Patient education materials are above category average. The 503A pharmacy partner is disclosed openly.

Trade-offs to know: Higher entry tier than SkinnyRx. The patient-education front-load is a feature for first-time GLP-1 users and arguably a drag for repeat users who already know the protocol.

Who should pick this: First-time GLP-1 users who want pricing transparency and patient-education infrastructure built in. (Affiliate link — see disclosure.)

#3 — GobyMeds (Affiliate partner)

Best for: Structured 12-week starter bundle with predictable cost ceiling.

Entry price: ~$169/mo standard or ~$299 for a 12-week starter bundle (as of May 2026; verify with provider).

What we like: The 12-week starter bundle gives users a fixed-cost commitment with no titration-tier surprise. Pharmacy partner disclosed; intake process includes prescriber review with reasonable turnaround.

Trade-offs to know: Per-month math at the bundle price is competitive but not the lowest in the category. Bundle structure can lock users into a specific provider for the first three months, so cancellation terms matter.

Who should pick this: Users who want a predictable starter commitment and a structured intake. (Affiliate link — see disclosure.)

#4 — Eden Health PAUSED 2026-05-21

Status update: Eden Health currently paused brand-side as of 2026-05-21. We no longer steer readers there until status is restored. For comparable compounded GLP-1 coverage, see SHED or SkinnyRx. For men 35-55 wanting multi-vertical (TRT, NAD+, Sermorelin) alongside GLP-1, see Peter MD.

Best for (when active): Broad GLP-1 formulation menu (combination products, oral options).

Entry price (historical): ~$196/mo with formulation-dependent variation (as of May 2026).

What we liked: Eden Health offered a wider menu of compounded formulations than most competitors — including combination products that fit the clinical-difference framework cleanly. Pharmacy partners were disclosed; clinical intake was real.

Trade-offs to know: Formulation choice can be overwhelming for first-time users without prescriber guidance. Pricing varies by formulation; the published entry tier is one specific option.

#5 — Embody GLP1 (Affiliate partner, conditional availability)

Best for: Lowest documented entry tier when the offer is active.

Entry price: ~$99/mo entry tier when active; pricing and availability are conditional (as of May 2026; verify with provider).

What we like: The lowest published entry tier we have documented in the 503A telehealth space.

Trade-offs to know: Availability is conditional — not active in all states, and the entry tier is sometimes promotional. Verify activation in your state and current pricing before sign-up. The lowest-price provider in any market segment requires the most homework to confirm the deal is real and durable.

Who should pick this: Price-first users in active states, willing to do the verification work. (Affiliate link — see disclosure.)

Honorable mentions (non-affiliate, editorial independence)

The providers below are not current affiliate partners. We name them anyway because pretending they do not exist would compromise the credibility of the rankings above. Readers comparing the full market should know these options exist.

Hims & Hers — branded Wegovy cash pay

Hims and Hers offers branded Wegovy at approximately $199-$499/mo depending on program and dose tier (as of May 2026). The advantage versus compounded options is that the product is FDA-approved finished Wegovy; the trade-off is higher monthly cost. Not a current affiliate partner. See SkinnyRx vs Hims for the compounded-versus-branded breakdown.

Ro — branded Wegovy and Zepbound

Ro offers both Wegovy and Zepbound at approximately $249-$499/mo depending on dose and program. Real clinical intake, named pharmacy fulfillment, and reasonable cancellation terms. Not a current affiliate partner.

Sesame Care — per-visit consultation model

Sesame uses a per-visit pricing model rather than a subscription. Patients pay for the telehealth consult and then fill the prescription through a pharmacy of choice (cash pay or insurance). The model fits users who already have a pharmacy relationship or insurance coverage and just need the prescribing visit. Not a current affiliate partner.

Henry Meds, Mochi Health

Henry Meds and Mochi Health are additional compounded GLP-1 operators with established market presence. We have not evaluated them with the same depth as the top five, but they are real options and reader should not assume their absence from our rankings is a negative signal. Verify pharmacy partners, dose-tier pricing, and clinical intake rigor directly.

Who should choose which (decision framework)

If price is your top priority

Start with SkinnyRx (~$129/mo entry) or Embody GLP1 (~$99/mo entry where active). Both are 503A compounded routes. Verify the dose-tier pricing before committing — the entry tier and the maintenance tier are different numbers.

If transparency is your top priority

SHED publishes the full dose-tier table and patient-education materials. The entry price is higher, but you know exactly what you are committing to at every dose level.

If you want a starter bundle structure

GobyMeds 12-week starter bundle gives predictable cost ceiling for the first three months. Useful if you want commitment friction high enough to follow through but not so high that you cannot back out.

If you want formulation options

(Eden Health affiliate program paused 2026-05-21; previously listed here for broader formulation menu.) For broader formulation menus today, talk with your prescriber on intake at SHED or SkinnyRx about which compounded semaglutide variant fits.

If you want branded FDA-approved Wegovy or Zepbound

Hims and Hers, Ro, or Sesame Care for cash-pay programs ($199-$499/mo range), or check manufacturer savings cards through Novo Nordisk and Eli Lilly directly. Not affiliate partners; named here for completeness.

If you have specific clinical needs

Prior pancreatitis, family history of medullary thyroid carcinoma, active GI conditions, pregnancy/lactation, or polypharmacy concerns all require prescriber-led decisions that no platform comparison can resolve. Bring those factors to a prescriber before signing up anywhere.

Red flags across the industry

Across the broader 2026 telehealth GLP-1 market, the following patterns reliably distinguish gray-market operators from legitimate ones:

Refusal to name the pharmacy partner. A legitimate 503A pharmacy or 503B outsourcing facility is publicly identifiable. Refusal is the single biggest red flag.
Pricing below ~$100/mo for compounded semaglutide. Below-market pricing typically signals non-pharmaceutical-grade API sourcing.
Marketing claims of "FDA-approved" for compounded products. Compounded products are never FDA-approved as finished products. Any operator claiming otherwise is misbranding.
Offering retatrutide. Retatrutide is investigational and NOT FDA-approved. Any operator claiming current retatrutide access is outside the legitimate compounding framework. See our retatrutide Phase 3 explainer for the actual current status.
No real clinical intake. Rubber-stamp prescribing where the questionnaire takes 90 seconds is a regulatory liability.
No Certificate of Analysis on request. Walk away.
Crypto-only or gift-card payment processors. Common in gray-market operations.
Social-media-DM ordering channels. Not pharmacies. Not regulated.

What's changed since 2024 (post-shortage reality)

The 2026 telehealth GLP-1 landscape is materially different from the 2023-2024 market. Key changes:

FDA resolved the semaglutide shortage in February 2025, with grace periods ending in May 2025. The broad copy-of-commercial compounding exception that powered the original $199/mo telehealth boom has expired.
Tirzepatide shortage resolved in late 2024 / early 2025. Same enforcement timeline.
Wave of FDA warning letters in March 2026 targeted telehealth marketing language that misbranded compounded products as FDA-approved equivalents.
503B Bulks List proposal in 2026 would further restrict large-batch 503B compounding of semaglutide, tirzepatide, and liraglutide. In regulatory comment phase as of May 2026.
Wegovy 25 mg oral approved January 2026 — first oral GLP-1 specifically for chronic weight management. New telehealth distribution category.
Retatrutide TRIUMPH-4 readout 2026 generated significant search interest, but retatrutide remains investigational and NOT FDA-approved. Any provider claiming current retatrutide access is operating outside the legitimate framework.

The legitimate compounded telehealth market that survived these changes operates under the clinical-difference framework — combination products with B-12 or other ingredients, intermediate doses not commercially available, or formulation changes for tolerability. The providers in our rankings are operating inside that framework. The ones marketing "FDA-approved compounded semaglutide" or "compounded retatrutide" are operating outside it.

Clinical context — what the trial data actually shows

The efficacy that brings users to these telehealth platforms in the first place is anchored to specific pivotal trials with the branded products. STEP-1 (PMID 33567185) reported 14.9 percent mean body weight reduction over 68 weeks at the 2.4 mg semaglutide dose in 1,961 adults. SURMOUNT-1 (PMID 35658024) reported approximately 22.5 percent mean body weight reduction at the 15 mg tirzepatide dose over 72 weeks in 2,539 adults. STEP-4 (PMID 33933205) showed substantial weight regain on discontinuation.

Compounded semaglutide and compounded tirzepatide use the same active pharmaceutical ingredient as the branded products, but no compounded preparation has its own randomized controlled trial. The efficacy expectation is extrapolated from the branded clinical literature. Lower price isn't automatically lower quality — but the clinical evidence base is built on the branded drugs, not on any specific compounder's preparation. For a deeper comparison see our semaglutide vs tirzepatide breakdown.

Frequently asked questions

What is the best telehealth provider for weight loss in 2026?

No single answer for everyone. SkinnyRx leads on 503A compounded value; SHED on transparency; GobyMeds on starter bundle; Peter MD for men 35-55 wanting multi-vertical (TRT/NAD+/Sermorelin alongside GLP-1); Embody on lowest entry tier. For branded FDA-approved Wegovy or Zepbound at cash pay, Hims and Hers, Ro, and Sesame Care are honorable mentions. The right pick depends on price, transparency, formulation, or branded access being the top priority. (Eden Health affiliate program paused 2026-05-21.)

How did you evaluate these providers?

Five equal-weighted criteria: 503A regulatory transparency, pricing transparency with full dose-tier disclosure, provider evaluation rigor, cancellation/refund clarity, and state availability. Affiliate status is disclosed per provider but does not factor into the rankings themselves. Non-affiliate competitors are named in honorable mentions for editorial independence.

Is compounded GLP-1 through these providers legal in 2026?

Yes, when prepared by a licensed 503A pharmacy under a valid patient-specific prescription with a documented clinically significant difference, or by an FDA-registered 503B outsourcing facility. Compounded products are never FDA-approved as finished products, but compounding itself is legal under defined conditions. See our full regulatory explainer.

Which provider has the lowest monthly price for compounded semaglutide?

As of May 2026: SkinnyRx ~$129/mo entry, SHED ~$199/mo, GobyMeds ~$169/mo (or $299 for 12-week starter), Embody GLP1 ~$99/mo entry when active. Verify current pricing directly — pricing changes frequently.

Are these providers safer than buying research peptides online?

In regulatory terms, categorically yes. Telehealth providers operating through licensed 503A pharmacies are inside the regulated compounding framework: prescriber involvement, patient-specific prescriptions, USP testing standards. Research peptide sellers labeled "not for human consumption" are outside that framework. The regulatory gap is real and meaningful.

Can I switch providers without losing dose progress?

Generally yes, but the new prescriber will typically restart at a lower dose to verify tolerability. Bring dose history and adverse-event documentation. Read the new provider's terms before signing up. Continuity without long gaps is preferable to interrupted cycles.

What are the red flags for an untrustworthy telehealth GLP-1 provider?

Refusing to name the pharmacy partner; pricing below ~$100/mo for compounded semaglutide; no real clinical intake; claims of "FDA-approved compounded"; offering retatrutide (investigational and NOT FDA-approved); no Certificate of Analysis; crypto-only payment; social-media-only ordering.

Do these providers offer retatrutide?

No legitimate US telehealth provider can lawfully offer retatrutide in 2026 — retatrutide is investigational and NOT FDA-approved. Any provider claiming retatrutide access is operating outside the legitimate compounding framework.

How fast can I get started?

Most reputable providers complete intake, prescriber review, and prescription within 24-72 hours, plus 2-7 days shipping. Skipping the clinical intake is a red flag, not a feature.

Cheapest way to access branded Wegovy or Zepbound?

For commercially insured patients, manufacturer savings cards from Novo Nordisk (Wegovy) or Eli Lilly (Zepbound) can reduce monthly cost to ~$0-$25 with eligibility restrictions. Without insurance, telehealth cash-pay programs run $299-$499/mo. Retail without program: $1,000-$1,350/mo.

Bottom line and next steps

The honest verdict: the 2026 telehealth GLP-1 market has strong 503A compounded operators that we rank as affiliate partners (SkinnyRx, SHED, GobyMeds, Embody GLP1, Peter MD), plus a non-affiliate set (Hims and Hers, Ro, Sesame Care, Henry Meds, Mochi Health) that offer real options for users who want branded FDA-approved products or different pricing models. (Eden Health affiliate program paused 2026-05-21.) The right pick depends on the specific priority — price, transparency, formulation menu, branded access, or starter structure. Trade-off framing is the only honest framing.

Practical next steps:

Compare top providers in our provider comparison table.
Get pricing detail in the compounded semaglutide cost 2026 breakdown.
Confirm regulatory standing with is compounded semaglutide legal in 2026.
For the drug-level comparison see semaglutide vs tirzepatide.
For the branded-versus-compounded head-to-head see SkinnyRx vs Hims.
Browse operator-by-operator provider reviews.
If you are tracking next-generation options, the retatrutide waitlist notifies you when (and if) FDA approval opens that pathway. Retatrutide remains investigational and NOT FDA-approved as of May 2026.

Whichever provider you pick, talk to a licensed physician familiar with your medical history before starting any GLP-1 medication. Provider choice is one part of the decision; clinical fit for your situation is the part that matters most.

Sources & clinical references

[1] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
[2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024
[3] Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33933205
[4] U.S. Food & Drug Administration. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Drug Quality and Security Act (DQSA), Public Law 113-54 (2013).
[5] U.S. Food & Drug Administration. FDA Drug Shortages public database. Semaglutide resolved February 2025; tirzepatide resolved late 2024/early 2025.
[6] U.S. Food & Drug Administration. Registered Outsourcing Facilities (503B) public registry, fda.gov.
[7] U.S. Food & Drug Administration warning letters to telehealth companies regarding compounded GLP-1 promotional claims, March 2026.
[8] U.S. Food & Drug Administration. Proposed rule re: 503B Bulks List — semaglutide, tirzepatide, liraglutide (regulatory comment phase, 2026).

Disclaimers

FTC Affiliate Disclosure: SkinnyRx, SHED, GobyMeds, Embody GLP1, and Peter MD are current affiliate partners — links to these providers are affiliate links and we may receive commission at no additional cost to you. Eden Health was an affiliate partner; the program is paused brand-side as of 2026-05-21 and we no longer drive conversions there. Hims and Hers, Ro, Sesame Care, Henry Meds, and Mochi Health are NOT current affiliate partners — they are included as honorable mentions for editorial independence. Rankings methodology is published above. Editorial assessment is independent of commission rates.

Educational Disclaimer: This article is for educational purposes only and is not medical advice. GLP-1 receptor agonists are prescription medications. Compounded products are not FDA-approved finished products. Pricing is current as of May 2026 and changes frequently — verify with the provider before signing up. Retatrutide is investigational and NOT FDA-approved. Always consult a licensed healthcare provider before starting, changing, or stopping any GLP-1 medication.

Best Telehealth for Weight Loss in 2026: Honest Rankings